Depression is common among cancer survivors but current screening approaches are not adequate. To help develop better strategies to screen for depression among cancer survivors, we will conduct a pilot randomized controlled trial with cancer survivors to evaluate whether a text message based approach to depression screening is feasible, acceptable, and potentially more effective than existing standard of care approaches to depression screening among cancer survivors.

Depression is common among cancer survivors but current screening approaches are not adequate. To help develop better strategies to screen for depression among cancer survivors, we will conduct a pilot randomized controlled trial with cancer survivors to evaluate whether a text message based approach to depression screening is feasible, acceptable, and potentially more effective than existing standard of care approaches to depression screening among cancer survivors.

Depression is common among cancer survivors but current screening approaches are not adequate. To help develop better strategies to screen for depression among cancer survivors, we will conduct a pilot randomized controlled trial with cancer survivors to evaluate whether a text message based approach to depression screening is feasible, acceptable, and potentially more effective than existing standard of care approaches to depression screening among cancer survivors.

Depression is common among cancer survivors but current screening approaches are not adequate. To help develop better strategies to screen for depression among cancer survivors, we will conduct a pilot randomized controlled trial with cancer survivors to evaluate whether a text message based approach to depression screening is feasible, acceptable, and potentially more effective than existing standard of care approaches to depression screening among cancer survivors.

Depression is common among cancer survivors but current screening approaches are not adequate. To help develop better strategies to screen for depression among cancer survivors, we will conduct a pilot randomized controlled trial with cancer survivors to evaluate whether a text message based approach to depression screening is feasible, acceptable, and potentially more effective than existing standard of care approaches to depression screening among cancer survivors.

Depression is common among cancer survivors but current screening approaches are not adequate. To help develop better strategies to screen for depression among cancer survivors, we will conduct a pilot randomized controlled trial with cancer survivors to evaluate whether a text message based approach to depression screening is feasible, acceptable, and potentially more effective than existing standard of care approaches to depression screening among cancer survivors.

Depression is common among cancer survivors but current screening approaches are not adequate. To help develop better strategies to screen for depression among cancer survivors, we will conduct a pilot randomized controlled trial with cancer survivors to evaluate whether a text message based approach to depression screening is feasible, acceptable, and potentially more effective than existing standard of care approaches to depression screening among cancer survivors.

This study is for patients scheduled for a bronchoscopy, a procedure that allows doctors to examine lungs and airways for evaluation of suspicious lung nodules. Those who give consent to participate in this study will be randomized into one of two lung biopsy sampling method groups based on the Rapid On Site Evaluation of the initial sample obtained by the doctor performing the bronchoscopy as part of the standard of care procedure for the patient. the potential groups the subject will be randomized into are: Cryoprobe or transbronchial biopsy needle. These devices are used with a bronchoscope to obtain lung tissue biopsy samples and are being evaluated to determine which is better for confirming a diagnosis. All procedures will be done via standard of care and screening will be accomplished via medical chart review. 7 days following the procedure, a member of the study team will check the subjects medical chart to assess whether any adverse events have occurred.

This study is designed as a prospective, multi-centered, double-blind, randomized, delayed-stimulation/ sham-stimulation controlled 12-month study to evaluate the effectiveness and safety of bilateral stimulation of the subcallosal cingulate white matter (SCCwm) using the Infinity™ Deep Brain Stimulation (DBS) system as an adjunctive treatment of non-psychotic unipolar Major Depressive Disorder (MDD) for adults who are experiencing a Major Depressive Episode (MDE) with inadequate response to 4 or more antidepressant treatments.

This study is for patients that have been diagnosed with high risk neuroblastoma. This study is testing an investigational drug called Dinutuximab, which will be combined with standard care induction and transplant. "Investigational" means it has not been approved by the United States Food and Drug Administration (FDA).
The primary purpose of this study is to compare treatment outcomes of participants who are assigned to early chemoimmunotherapy (Dinutuximab and Sargramostim) during Induction to treatment outcomes of participants who are not assigned to treatment that includes early chemoimmunotherapy. Participants will be randomized to the standard of care arm of the trial or the standard of care arm plus chemoimmunotherapy (like flipping a coin). The investigational drug is given to participants through IV infusion. Participants in this study can expect to be in this study for a total of five years.